Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immatics N.V. (IMTX : NSDQ)

• Company Description    Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. Immatics N.V., formerly known as ARYA SCIENCES, is based in Tuebingen, Germany. Number of Employees: 407

• Price / Volume Information    Yesterday's Closing Price: $11.62 Daily Weekly Monthly 20 Day Moving Average: 531,888 shares Shares Outstanding: 134.07 (millions) Market Capitalization: $1,557.91 (millions) Beta: 1.31 52 Week High: $12.41 52 Week Low: $4.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.22% -0.88% 12 Week 14.71% 6.04% Year To Date 10.67% -3.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL PAUL EHRLICH-STRASSE 15 - TUBINGEN,2M 72076 DEU ph: 49-7071-539-7700 fax: - investorrelations@immatics.com https://immatics.com

• General Corporate Information    Officers Harpreet Singh - Chief Executive Officer Steffen Walter - Chief Operations Officer Venkat Ramanan - Chief Financial Officer Cedrik Britten - Chief Medical Officer Carsten Reinhardt - Chief Development Officer Peer Information Immatics N.V. (CORR.) Immatics N.V. (RSPI) Immatics N.V. (CGXP) Immatics N.V. (BGEN) Immatics N.V. (GTBP) Immatics N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N44445109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 134.07 Most Recent Split Date: (:1) Beta: 1.31 Market Capitalization: $1,557.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 22.14% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.92 Price/Cash Flow: - Price / Sales: 35.94 EPS Growth vs. Year Ago Period: -42.86% vs. Previous Quarter: -47.06% Sales Growth vs. Year Ago Period: -54.43% vs. Previous Quarter: -61.28% ROE 03/31/26 - -47.36 12/31/25 - -41.81 09/30/25 - -24.16 ROA 03/31/26 - -39.35 12/31/25 - -34.72 09/30/25 - -19.85 Current Ratio 03/31/26 - 8.78 12/31/25 - 11.72 09/30/25 - 7.36 Quick Ratio 03/31/26 - 8.78 12/31/25 - 11.72 09/30/25 - 7.36 Operating Margin 03/31/26 - -572.35 12/31/25 - -411.90 09/30/25 - -146.13 Net Margin 03/31/26 - -572.35 12/31/25 - -411.90 09/30/25 - -146.13 Pre-Tax Margin 03/31/26 - -574.58 12/31/25 - -411.13 09/30/25 - -149.99 Book Value 03/31/26 - 3.98 12/31/25 - 4.09 09/30/25 - 4.01 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©